Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.34 |
| ▸ | FNTB | P49356 | 1/20 | 0.34 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16029388 | 0.98 | KDM4E (0.43) | MAOBMAOAKDM4EAAK1CYP2D6 | |
| Hydrochloric Acid SCHEMBL30085698 | 0.98 | KDM4E (0.43) | MAOBMAOAKDM4EAAK1CYP2D6 | |
| SCHEMBL14820084 | 0.90 | MAOB (0.45) | MAOBMAOAKDM4EAAK1NOS2 | |
| SCHEMBL30108128 | 0.83 | PDE4B (0.46) | MAOBMAOAAAK1ARALDH1A1 | |
| SCHEMBL16279970 | 0.83 | PDE4B (0.46) | MAOBMAOAAAK1ARALDH1A1 | |
| SCHEMBL2774024 | 0.82 | HPGD (0.49) | MAOBMAOAARALDH1A1HPGD | |
| SCHEMBL8436504 | 0.82 | EGFR (0.47) | MAOBMAOAAAK1AR | |
| SCHEMBL13581220 | 0.81 | ALDH1A1 (0.55) | ARALDH1A1HPGD | |
| SCHEMBL89415 | 0.81 | EGFR (0.41) | MAOBMAOAKDM4EAAK1AR | |
| SCHEMBL16596421 | 0.80 | ALDH1A1 (0.57) | ARALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3851441-B1 | PROCESS FOR THE PREPARATION OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO) PROPANAMIDE | HOFFMANN LA ROCHE (CH) | 2023-06-28 | — | — | EP | disclosed |
| EP-3851441-A1 | PROCESS FOR THE PREPARATION OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO) PROPANAMIDE | F. Hoffmann-La Roche AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| EP-3845540-A1 | INTERMEDIATES FOR THE SYNTHESIS OF BENZOXAZEPIN COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2021-07-07 | — | — | EP | disclosed |
| EP-3555107-B1 | PROCESS FOR THE PREPARATION OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO)PROPANAMIDE | HOFFMANN LA ROCHE (CH) | 2021-02-17 | — | — | EP | disclosed |
| WO-2018109204-A1 | PROCESS FOR THE PREPARATION OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO) PROPANAMIDE | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-21 | — | — | WO | disclosed |
| EP-2688891-B1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2017-11-15 | — | — | EP | disclosed |
| US-9670228-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170081341-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-03-23 | — | — | US | disclosed |
| US-9546178-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9303043-B2 | Process for making benzoxazepin compounds | GREENTECH, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9090628-B2 | Benzoxazepin compounds selective for PI3K P110 delta and methods of use | GENENTECH, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2845592-A1 | Benzoxazepin PI3K inhibitor compounds and methods of use | F. Hoffmann-La Roche AG (CH) | 2015-03-11 | — | — | EP | disclosed |
| US-20140288047-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140275523-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | GENENTECH, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275523-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | GENENTECH, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014140073-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-18 | — | — | WO | disclosed |
| US-8785626-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2711368-A1 | Benzoxazepin PI3K inhibitor compounds and methods of use | F. Hoffmann-La Roche AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-20140058098-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20130079331-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140058098-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | MAOB 2745/4885MAOA 3068/4885KDM4E 3058/4885 |
| US-20140288047-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | MAOB 2745/4885MAOA 3068/4885KDM4E 3058/4885 |
| US-20130079331-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | MAOB 2745/4885MAOA 3068/4885KDM4E 3058/4885 |
| US-20170081341-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | MAOB 2745/4885MAOA 3068/4885KDM4E 3058/4885 |
| US-20140275523-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | PIK3C2B, PIP4K2C, PIK3C2A | MAOB 1485/4885MAOA 1911/4885KDM4E 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.